SEARCH
Home
News
Fortune 500
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Great Place to Work
Tech
AI
Innovation
Cybersecurity
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Success
Future of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Analytics
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Home
News
FORTUNE 500
FORTUNE 500
FORTUNE SEA 500
Fortune 500 Europe
Fortune Global 500
Fortune China 500
Great Place to Work
Tech
Tech
AI
Innovation
Cybersecurity
Finance
Finance
Personal Finance
Real Estate
Economy
Banking
Investing
Crypto
Leadership
Leadership
Success
Future of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Rankings
Analytics
Multimedia
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Asia
Europe
Analytics
Ashleigh Furlong
Stay informed with Ashleigh Furlong’s coverage and analysis for Fortune.
Tech
AstraZeneca to buy cell therapy biotech for up to $1 billion
By
Ashleigh Furlong
and
Bloomberg
Health
WHO offers early retirement to cut costs ahead of U.S. exit
By
Bloomberg
,
Ashleigh Furlong
, and others
Finance
Sanofi profit lifted by early vaccine sales, dupixent growth
By
Ashleigh Furlong
,
Tim Loh
, and others
Health
Hair loss drug probed in Europe over link to suicidal thoughts
By
Ashleigh Furlong
and
Bloomberg
Retail
Victory for drugmakers GSK and Boehringer in $640 million Zantac cancer lawsuit, but thousands still to come
By
Jef Feeley
,
Ashleigh Furlong
, and others
Health
How GSK CEO Emma Walmsley kept her job and turned a belligerent activist investor into an ally
By
Ashleigh Furlong
,
Sabah Meddings
, and others
Retail
AstraZeneca sets bold revenue target as CEO aims to double sales to $80 billion by 2030
By
Ashleigh Furlong
and
Bloomberg
Health
Weaning off Ozempic slowly instead of quitting abruptly can help prevent patients from regaining weight, study says
By
Ashleigh Furlong
and
Bloomberg
Retail
AstraZeneca encounters a surge in shares as profits exceed expectations, buoyed by demand for cancer drugs
By
Ashleigh Furlong
and
Bloomberg
Retail
Wegovy and Ozempic have ignited a gold rush in pharma as well as an upsurge in fake ‘skinny jabs’, leading to surge in hospitalizations
By
Ashleigh Furlong
and
Bloomberg